Indications for DDAVP NASAL SPRAY:
Central diabetes insipidus.
10–40mcg once daily into 1 nostril (or 40mcg divided into 2–3 daily doses). Use other forms for doses <10mcg or doses other than multiples of 10mcg.
<4yrs: not recommended. ≥4yrs: initially 10mcg once daily into 1 nostril; may increase to 30mcg once daily (or in 2 divided doses, usually 20mcg in the AM and 10mcg in the PM). Use other forms for doses <10mcg.
Moderate to severe renal impairment (CrCl <50mL/min). Hyponatremia, or history of.
Monitor fluid intake, urine volume and osmolality. Fluid/electrolyte imbalance (eg, cystic fibrosis). Habitual or psychogenic polydipsia. Coronary artery insufficiency. Hypertension. Inj: Predisposition to thrombosis. Nasal mucosal changes (nasal forms). Young children. Elderly. Pregnancy. Nursing mothers.
Caution with other pressor agents, drugs that may increase the risk of water intoxication with hyponatremia (eg, tricyclic antidepressants, SSRIs, chlorpromazine, opiates, NSAIDs, lamotrigine, carbamazepine). Possible convulsions with oxybutynin, imipramine.
Headache, nausea, flushing, abdominal cramps, vulval pain, water intoxication, hyponatremia, nasal congestion or rhinitis (nasal forms), inj site reaction; rare: changes in BP, severe allergic reactions, seizures in children from plasma hypoosmolality, thrombotic events (inj).
Tabs—100; Nasal spray—5mL (50 sprays); Rhinal tube—2.5mL (w. 2 rhinal tubes); Amp (1mL)—10; Multi-dose vial (10mL)—1